Alicia Granados | Head, Global Rare Diseases Medical Scientific Advocacy

Alicia Granados, Head, Global Rare Diseases  Medical Scientific Advocacy, SANOFI

Alicia Granados, MD & PhD in Public Health from the University of Barcelona. She is a certified specialist in respiratory medicine. Currently serving as Global Head Rare Disorder Medical Scientific Advocacy & Insights at a big biopharma, Sanofi, where she has been heading its global Health Technology Assessment (HTA) strategy until 2021. She was a founding member of INAHTA, the first international HTA network; as well as the first HTA joint initiative in Europe, EUR-ASSESS, predecessor of EUnetHTA meanwhile heading the Catalan Agency for HTA, CAHTA, currently named AQUAS. She is also former President of the International Society for Technology Assessment in Health Care (ISTAHC) and Chair of the Committee for the Creation of a new HTA Society: HTAi, of which she was the first president. Currently serving, on a voluntary basis, as Chair of the HTAi Policy Forum Series, Advisory Committee. Dr. Granados has been temporary advisor of several UN agencies on Evidence Based Health Care, and Acting Regional Advisor of WHO European Office, leading the Health Evidence Network. She has been Associate Professor of Medicine at the University of Barcelona and has more than 60 scientific and policy articles published. Dr. Granados is former President of Autonomous University of Barcelona’s Board of Trustees, Advisor to the Catalan Government President on wellness and economic reactivation and growth (CAREC) and of the Department of Health Advisory Council of Catalan Government.


Day 1 - Wednesday 23 October @ 16:40

Panel: Evidence Assessment in rare. Why do we need a change in Paradigm. The work of HTAi RDIG

last published: 04/Jul/24 16:55 GMT

back to speakers